Navigation Links
Two-year data for Angiotech's Vascular Wrap Paclitaxel-Eluting Mesh,to be Presented at European Vascular Symposium

STRASBOURG, France and VANCOUVER, April 26, 2007 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. , a global specialty pharmaceutical and medical device company, announced that the two-year data from its European pivotal trial examining the Vascular Wrap(TM) Paclitaxel-Eluting Mesh ("Vascular Wrap(TM)") will be presented today at a scientific forum in Europe. The two-year study examined the safety and efficacy of the Vascular Wrap(TM) for use in arterial bypass surgery in patients with peripheral arterial disease (PAD). Dr. Lajos Matyas is presenting the results at the 2007 European Symposium of Vascular Biomaterials (ESVB) in Strasbourg, France.

"We are pleased to have this opportunity to present these encouraging results from our two-year European Vascular Wrap(TM) study to the physicians, researchers and other healthcare professionals at ESVB," said Dr. Rui Avelar, Chief Medical Officer at Angiotech.

"The results of this 109-patient study suggest that the Vascular Wrap(TM) combined with an ePTFE graft may be a promising future therapy option for patients with PAD who require arterial bypass surgery," said Dr. Lajos Matyas, a lead investigator based in Miskolc, Hungary, who enrolled the highest number of patients out of the nine clinical centres in Europe involved in the study.

Angiotech initially released the results from the two-year Vascular Wrap(TM) study in November 2006. The objectives of this two-year study were to assess the safety and clinical performance of the Vascular Wrap(TM) in combination with an ePTFE vascular graft following surgery to treat patients suffering from advanced peripheral arterial disease in their lower limbs. The Vascular Wrap(TM) in combination with an ePTFE graft was compared to a control group of patients that received standard of care - an ePTFE graft alone. Some of the highlights of the two-year study that will be presented at ESVB include:


'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
3. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
4. Abbott to Present New Data Across its Vascular Portfolio at the American College of Cardiologys 56th Annual Scientific Session
5. Taxus VI Clinical Trial Demonstrates Positive Long-Term Outcomes for Moderate-Release Paclitaxel-Eluting Stent at Four Years
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:7/11/2014)... 2014 On Thursday, July ... the Dow Jones Industrial Average finished the day 0.42% lower ... 0.41%. The losses were broad based as eight out of ... Health Care Sector Index ended the day at 711.88, down ... one month. Investor-Edge has initiated coverage on the following equities: ...
(Date:7/11/2014)... 11, 2014 Show ... & Health Expo 2014 were a brand ... London , plus a ...          (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... )      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... CLEVELAND , July 10, 2014  The U.S. ... a three-year grant to University Hospitals (UH) Case Medical ... a new national model aimed at improving care for ... Oncology Care," the project will test a unique model ... patients with late-stage disease, significant comorbidities, or demonstrated need ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... National Institute of,Standards and Technology (NIST) has selected ... Commerce Department,s Advanced Technology Program,(ATP), a peer-reviewed competition. ... the early-phase Michigan biotechnology company developing,drug therapies to ... disorders. Velcura scientists have discovered a family ...
... YORK, Sept. 27 Immtech Pharmaceuticals,Inc. (Immtech) (Amex: ... Food and Drug,Administration of the People,s Republic of ... for conducting a Phase III clinical,trial with pafuramidine, ... Pneumocystis pneumonia (PCP). Pafuramidine is among the first,drugs ...
Cached Medicine Technology:NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease 2Chinese SFDA Grants Immtech Fast Track Status 2Chinese SFDA Grants Immtech Fast Track Status 3
(Date:7/11/2014)... Obese and overweight firefighters are not receiving ... according to new research from The University of ... National guidelines state that health care professionals (HCPs) ... a healthy weight. Firefighters have high rates of ... of line-of-duty deaths in firefighters. This study assessed ...
(Date:7/11/2014)... The Corn Farming industry ... on the heels of fresh biofuel demand. The Federal ... a larger share of their farmland to cultivating high-value ... required the mixing of 5.0% renewable content in gasoline ... United States created a key export market for Canadian ...
(Date:7/11/2014)... Reinberg HealthDay Reporter THURSDAY, ... protect children from the worldwide scourge of dengue fever was ... the vaccine only prevented dengue fever in 56 percent of ... shots, it protected more than 88 percent of them from ... to hospitalization, and sometimes death. "This vaccine has already ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... CA. Over the years Luke Bryan has been honored by ... he do well at award shows, but each summer, he hits ... tours of the genre and this summer is more of the ... to the popularity and success that is currently entitled to Luke ...
(Date:7/11/2014)... Riverside Health System became the first provider ... in late 2012 and now, in partnership with Williamsburg Landing, ... the Williamsburg and Newport News region. , Also known as ... to independent older adults who wish to remain in their ... of continuing care services as well as control over the ...
Breaking Medicine News(10 mins):Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Dengue Fever Vaccine Shows Some Promise in Trial 2Health News:Dengue Fever Vaccine Shows Some Promise in Trial 3Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 2Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 3Health News:Riverside and Williamsburg Landing Partner to Offer First of Its Kind Service to Virginians Who Want to Age in Place 4
... not quintessentially masculine, women in their fertile phase are ... women paired with George Clooney types. But women ... to their partners, a recent study co-authored by a ... a man,s intelligence has no effect on the extent ...
... Residents of Cuyahoga County, and later Lorain County, will ... of a national resource for childhood growth and development. ... of children,s health ever conducted in the United States. ... The study will enroll women who are pregnant ...
... -- People over age 65 are at increased risk for ... study finds. Latent tuberculosis occurs when TB bacteria lurk ... has no symptoms of TB and is not contagious. However, ... cause tuberculosis, which can be fatal if it goes untreated. ...
... has received a boost from a surprising source: the 2009 ... 2009 H1N1 strain developed antibodies that are protective against a ... Medicine and the University of Chicago have found. The results ... Medicine . "Our data shows that infection with the ...
... one of today,s most exciting scientific and clinical areas. ... rulings by regulatory bodies or ethical controversies. These often ... ethicists, legislators, the media and the public. ESHRE,s ... of the world,s leading experts in reproductive medicine gather ...
... Race and ethnicity play major roles in whether people get ... much less likely to undergo colonoscopies than white people. Now, ... people live. Research by oncologist Dr. Thomas Semrad ... Center found that location makes a big difference in rates ...
Cached Medicine News:Health News:Men with macho faces attractive to fertile women, researchers find 2Health News:Men with macho faces attractive to fertile women, researchers find 3Health News:Case Western Reserve University School of Medicine launches the National Children's Study 2Health News:Treating Latent TB After 65 Raises Serious Side-Effect Risk 2Health News:Pandemic flu strain could point way to universal vaccine 2Health News:Pandemic flu strain could point way to universal vaccine 3Health News:ESHRE bridges East and West for its 2012 Congress in Istanbul 2Health News:Geography May Influence Colon Cancer Screening Rates 2
... Beta 200 ophthalmoscope, ... glare-free direct ophthalmoscope. Heine's ... patent #4,963,014) along with ... construction, make the Beta ...
... optics. The separation of illumination and observation ... system avoids corneal and iris reflex (Gullstrand-principle). ... the whole of the illuminated section of ... Conventional ophthalmoscopes often let you see only ...
... Beta 200S is the first ... combination of patented aspherical optics ... range of corrective lenses from ... single diopter steps. A perfectly-focused ...
With the unique automatic focus system, Autofoc 2 remains the instrument of choice for direct ophthalmoscopy. Includes XHL halogen bulb....
Medicine Products: